Humanized EL4-hCD19-LZ Reporter Tumor Cell Line

Reporter Immune Checkpoint Cell Lines

Design of the EL4-hCD19-LZ cell line

The EL-4 cell line was established from a C57BL/6 murine lymphoma. These cells form tumors in syngeneic models, upon subcutaneous and systemic (i.v.) injection, in immunocompetent mice.

We generated an EL4-hCD19-LZ clonal cell line expressing high levels of human CD19 (NCBI GeneID: 930), and an optimized dual fusion reporter luciferase-ZsGreen (LZ). EL4-hCD19-LZ cells form tumors in vivo when injected subcutaneously. Luciferase-ZsGreen (LZ) control cells are available.



Request a quote here to get pricing, offers and EL4-CD19-LZ model information by phone or email.


EL4-hCD19-LZ features

  • Express a fully human CD19
  • Express a luciferase-ZsGreen (LZ) fusion reporter
  • Form tumors upon subcutaneous injection in fully immunocompetent mice


EL4-hCD19-LZ validation*

EL4-hCD19-LZ_img01EL4-hCD19-LZ cells homogeneously express human CD19 in vitro

Expression analysis by flow cytometry. Human CD19 expression was assessed in EL4 parental cell line (left), human control cells – PBMC (center), and EL4-hCD19-LZ cell line (right).

EL4-hCD19-LZ_img02EL4-hCD19-LZ cells form infiltrated tumors in immunocompetent mice

Left figure. Humanized CD3 C57/Bl6 mice were injected (s.c.) with 1x106 EL4-hCD19-LZ cells. Tumor growth was measured every 2 to 4 days. Tumor size (mm3) = (width²*length)/2.

Right figure. Medium (200 mm3) and large (800 mm3) tumors were collected and tumor composition was determined by flow cytometry.

* For more validation data please contact us.

Ready to be shipped to your lab

  • Biosafety level BSL1, according to Kerafast guidelines (parental cell line provider)
  • Studies can be carried out at your site or at your favorite CRO
  • Models provided with FTO on patent-protected technologies used for model generation

Are you looking for another target?
Please contact us.